PDUFAconf 0.99

relacorilant — PDUFA

$CORT · CORCEPT THERAPEUTICS INC · hypertension secondary to hypercortisolism

Event date

July 11, 2026

in 45 days

Sponsor runway

5+ yrs

$338.2M liquid

Evidence

“The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026 for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.”

Source: Press release · 2025-12-31View press release ↗

Comparable historical pdufas· last 5 years · same event type

75% hit rate (3/4)

Ticker	Drug	Date	Outcome
$RCKT	kresladi	2026-03-28	success
$RYTM	imcivree	2026-03-20	success
$CYTK	aficamten	2025-12-26	unknown
$ALDX	reproxalap	2025-12-16	unknown
$BCRX	orladeyo	2025-12-12	success
$OMER	narsoplimab	2025-09-25	unknown
$BCRX	orladeyo (berotralstat)	2025-09-12	unknown
$ETON	et-400	2025-05-28	unknown
$ALDX	reproxalap	2025-04-02	failure
$IONS	olezarsen	2024-12-19	unknown

Recent insider activity· ±90 days

4 insiders · 0 buys · 2 sells

Gift

2026-05-13

Robb Gary Charles

Chief Business Officer

5,300 @ ——

Gift

2026-05-13

Robb Gary Charles

Chief Business Officer

1,000 @ ——

Exercise10b5-1

2026-05-05

Guyer William

Chief Development Officer

20,000 @ $21.65$433K

Sell10b5-1

2026-05-05

Guyer William

Chief Development Officer

20,000 @ $51.83$1.04M

Sell10b5-1

2026-05-01

BELANOFF JOSEPH K

Chief Executive Officer

40,000 @ $50.10$2.00M

Gift

2026-04-22

WILSON JAMES N

Director

2,000 @ ——

Date	Insider	Action	Shares	Price	Value
2026-05-13	Robb Gary CharlesChief Business Officer	Gift	5,300	—	—
2026-05-13	Robb Gary CharlesChief Business Officer	Gift	1,000	—	—
2026-05-05	Guyer WilliamChief Development Officer	Exercise10b5-1	20,000	$21.65	$433K
2026-05-05	Guyer WilliamChief Development Officer	Sell10b5-1	20,000	$51.83	$1.04M
2026-05-01	BELANOFF JOSEPH KChief Executive Officer	Sell10b5-1	40,000	$50.10	$2.00M
2026-04-22	WILSON JAMES NDirector	Gift	2,000	—	—

← All catalysts for $CORT